Raymond James Financial’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$93.9M Buy
1,608,354
+8,473
+0.5% +$500K 0.03% 586
2026
Q2
$89.7M Buy
1,599,881
+75,863
+5% +$3.95M 0.02% 622
2026
Q1
$72.7M Buy
1,524,018
+56,419
+4% +$2.47M 0.02% 652
2025
Q4
$56.8M Buy
1,467,599
+16,896
+1% +$644K 0.02% 761
2025
Q3
$51.2M Buy
1,450,703
+326,615
+29% +$11.8M 0.02% 795
2025
Q2
$40.5M Buy
1,124,088
+37,099
+3% +$1.23M 0.01% 887
2025
Q1
$33.8M Buy
1,086,989
+303,356
+39% +$9.6M 0.01% 949
2024
Q4
$20M Buy
+783,633
New +$20.8M 0.01% 1310

Other funds holding RPRX

Raymond James Financial's RPRX Position: Q3 2026 in Review

Raymond James Financial increased its Royalty Pharma (RPRX) stake by 0.53% in Q3 2026, buying an estimated $500K and bringing the position to 1,608,354 shares worth $93.9M. The position accounts for 0.03% of the portfolio, ranked #586.

Raymond James Financial first reported a position in RPRX in Q4 2024 and has held it in 8 quarters since. 701 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Raymond James Financial held 1,608,354 shares of Royalty Pharma worth $93.9M as of Q3 2026.
  • Raymond James Financial bought 8,473 Royalty Pharma shares in Q3 2026, an estimated $500K.
  • Royalty Pharma made up 0.03% of Raymond James Financial's portfolio in Q3 2026, its #586 holding.
  • Raymond James Financial first reported a position in Royalty Pharma in Q4 2024 and has held it in 8 quarters since.
  • 701 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.